



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Midodrine as adjunction support for Weaning off Norepinephrine in Septic Shock

Thesis

*Submitted for Partial Fulfillment of Master Degree
In Intensive Care Medicine*

By

Hussien Gamal Mohammed Hafez

*M.B. B.Ch. Faculty of Medicine Misr University
for science and technology*

Supervised By

Prof.Dr. Sherif Wadie Nashed

*Professor of Anesthesia, Intensive Care Medicine and Pain Management
Faculty of Medicine – Ain Shams University*

Dr. Fady Adib Abd El Malek Morkos

*Assistant of Anesthesia, Intensive Care Medicine and Pain Management
Faculty of Medicine – Ain Shams University*

Dr. Wael Abd El_Moneim Mohamed Abd El Wahab

*Lecturer of Anesthesia, Intensive Care Medicine and Pain Management
Faculty of Medicine – Ain Shams University*

Faculty of Medicine - Ain Shams University

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **Allah**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof.Dr. Sherif Wadie Nashed**, Professor of Anesthesia, Intensive care Medicine and Pain Management, Faculty of Medicine – Ain Shams University, for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Fady Adib Abd El Malek Morkos**, Assistant Professor of Anesthesia, Intensive Care Medicine and Pain Management, Faculty of Medicine – Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr.Wael Abd EL_Moneim Mohamed Abd El Wahab**, Lecturer of Anesthesia, Intensive Care Medicine and Pain Management, Faculty of Medicine – Ain Shams University, for his great help, active participation and guidance.*

*I would like to express my hearty thanks to all **my family** for their support till this work was completed.*

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Hussien Gamal Mohammed Hafez

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations.....	iii
Introduction	1
Aim of Work	3
Review of Literature	
Septic Shock.....	4
Management of Septic Shock.....	14
Midodrine in Septic shock Patients.....	25
Patients and Methods.....	31
Results	35
Discussion	49
Summary	56
Conclusion	57
Recommendation	58
References	59
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Baseline demographic characteristics among the studied groups	36
Table (2):	Baseline clinical characteristics among the studied groups	37
Table (3):	Mean arterial pressure (mmHg) among the studied groups	38
Table (4):	Serum lactate (mmol/L) among the studied groups	40
Table (5):	Average urine output (mL/kg/h) among the studied groups	42
Table (6):	NE weaning time (h) among the studied groups	43
Table (7):	NE dose (mg/day) among the studied groups.....	45
Table (8):	ICU stay (day) among the studied groups.....	46
Table (9):	Hospital stay (day) among the studied groups.	47
Table (10):	Survival among the studied groups.....	48

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Changes in the vascular endothelium in response to inflammatory stimuli during sepsis.....	9
Figure (2):	Pathogenesis of septic shock.....	13
Figure (3):	Changes from previous definitions were removal of severe sepsis and removal of SIRS criteria for non-septic inflammatory states.....	15
Figure (4):	Treatment of septic shock. On left, life-saving treatments	21
Figure (5):	Chemical structure of midodrine; C ₁₂ H ₁₈ N ₂ O ₄ ; molar mass 254.29 grams per mole	25
Figure (6):	Flow chart of the studied cases.....	35
Figure (7):	Mean arterial pressure among the studied groups.	39
Figure (8):	Mean arterial pressure elevation among the studied groups.	39
Figure (9):	Serum lactate among the studied groups.....	41
Figure (10):	Serum lactate reduction among the studied groups.	41
Figure (11):	Average urine output among the studied groups.	42
Figure (12):	NE weaning time among the studied groups.	43
Figure (13):	Kaplan meier curve for NE weaning among the studied groups.....	44
Figure (14):	NE dose among the studied groups.	45
Figure (15):	ICU stay among the studied groups.....	46
Figure (16):	Hospital stay among the studied groups.....	47
Figure (17):	Survival among the studied groups.....	48

List of Abbreviations

Abb.	Full term
BNP	B-Type Natriuretic Peptide
CRP	C-Reactive Protein
EGDT	Early goal-directed therapy
GD	Graves' Disease
GM-CSF	granulocyte-macrophage colony stimulating factor
HMGB-1	High mobility group box-1
ICAM1	Intercellular adhesion molecule 1
ICU	Intensive care units
IL-1ra	IL-1 receptor antagonist
IV	Intravenous
LFA1	Lymphocyte function-associated antigen 1
LOS	Length of stay
MAP	Mean arterial pressure
MIF	Migration inhibitory factor
MODS	Multiple organ dysfunction syndrome
MPO	Myeloperoxidase
NE	Norepinephrine
NF- κ B	Nuclear Factor Kappa B
NK	Natural killer
NO	Nitric oxide
PAF	Platelet- activating factor
PAI-1	Plasminogen activator inhibitor 1
PAMPs	Pathogen-associated molecular patterns

PCT	Procalcitonin
PGI2	Prostaglandin I2
PMN	Polymorph nuclear
PRRs.....	Pathogen recognition receptors
PSGL1	P-selectin ligand 1
ROS	Reactive oxygen species
SD.....	Standard deviation
SOFA.....	Sepsis-related] Organ Failure Assessment score
SSC.....	Surviving Sepsis Campaign
t1/2	The half-life
TFPI	Tissue factor pathway inhibitor
TLR	Toll-like receptors
TM	Thrombomodulin
t-PA	Tissue plasminogen activator
TXA2	Thromboxane A2
VE	Vascular endothelial

INTRODUCTION

Sepsis, “life-threatening organ dysfunction caused by a dysregulated host response to infection.” End organ damage is identified as an acute change in total Sequential [Sepsis-related] Organ Failure Assessment score (SOFA) ≥ 2 (**Rhodes et al., 2016**). Septic shock: A subset of sepsis “in which circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. These patients can be clinically identified by a vasopressor requirement to maintain a MAP ≥ 65 mmHg and serum lactate < 2 mmol/L in the absence of hypovolemia (**Singer et al., 2016**). Septic shock is the most challenging problem in critical care medicine and has a very high mortality, owing to the complex pathophysiology, the outcomes for septic shock patients remain disappointing (**Dombrovskiy et al., 2007**). Investigating the rational use of vasopressors in septic shock is very important. Thus far, most studies have focused on the rational use of different types of vasopressors (**Sandifer and Jones, 2013**).

The current guidelines recommend that vasopressors (norepinephrine as the first choice) be administered for hypotension refractory to initial fluid resuscitation and to maintain a mean arterial pressure (MAP) ≥ 65 mm Hg (**LeDoux et al., 2000**). Norepinephrine is a potent alpha-adrenergic agonist with minimal beta-adrenergic agonist effects. It can increase blood pressure successfully in patients with sepsis who remain hypotensive after fluid resuscitation. The dosage may

range from 0.2 to 1.5 $\mu\text{g/kg/min}$, and dosages as high as 3.3 $\mu\text{g/kg/min}$ have been used because of the α -receptor down regulation in sepsis. In patients with sepsis, indices of regional perfusion (eg, urine flow) and lactate concentration have improved after norepinephrine infusion (**Andre et al., 2020**). The rate of weaning of Norepinephrine is usually an empirical choice made by the treating in critically ill patients. It is generally agreed that fluid resuscitation and Norepinephrine should be initiated promptly to treat shock and organ failure, and rapidly restore the mean arterial pressure (MAP) to 60 to 90 mmHg (**Merouani et al., 2008**). Midodrine is an orally available α 1-adrenergic receptor agonist with a labelled indication for the treatment of symptomatic orthostatic hypotension (**Wright et al., 1998**). Its therapeutic effect is due to desglymidodrine, an active metabolite formed by enzymatic hydrolysis of midodrine. After oral administration, the prod rug reaches peak serum concentrations within 30 min and desglymidodrine reaches peak serum concentrations in 1 – 2 h (**Wright et al., 1998**). Due to midodrine's predictable pharmacologic response and favorable sympathomimetic effects in patients with orthostatic hypotension, it is utilized as an off-label treatment to provide hemodynamic support to facilitate the weaning of IV vasopressor infusions in ICU patients. The overall goal of midodrine administration is to minimize the adverse effects of IV vasopressors and decrease ICU length of stay (**Poveromo et al., 2016**).

AIM OF WORK

This study aims to evaluate whether oral administration of midodrine is an effective adjunct to standard therapy to reduce the duration of IV norepinephrine and allow earlier discharge from ICU compared to control patients.

Chapter 1

SEPTIC SHOCK

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, with septic shock being defined as a subset of sepsis with circulatory and cellular/metabolic dysfunction that is associated with a higher rate of mortality (*Shankar et al., 2016*).

Septic shock is a result of a systemic response to infection or multiple infectious causes. The precipitating infections that may lead to septic shock if severe enough include but are not limited to appendicitis, pneumonia, bacteremia, diverticulitis, pyelonephritis, meningitis, pancreatitis, necrotizing fasciitis, MRSA and mesenteric ischemia (*Gwon et al., 2012*).

It is a potentially fatal medical condition that occurs when sepsis, which is organ injury or damage in response to infection, leads to dangerously low blood pressure and abnormalities in cellular metabolism (*Hotchkiss et al., 2016*).

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) defined septic shock (*Singer et al., 2016*).

Proposed criteria for sepsis and septic shock

This proposal stems from the 2015 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3),